Drugs & Therapy Perspectives

, Volume 22, Issue 7, pp 1–5 | Cite as

Rifaximin is a safe and effective antibacterial for treating noninvasive traveller’s diarrhoea

Drug and Profile Reports


  1. 1.
    Ericsson CD. Travellers’ diarrhoea. Int J Antimicrob Agents 2003 Feb; 21(2): 116–24PubMedCrossRefGoogle Scholar
  2. 2.
    Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers’ diarrhea. J Travel Med 2001 Dec; 8Suppl. 2: S26–30PubMedCrossRefGoogle Scholar
  3. 3.
    Casburn-Jones AC, Farthing MJG. Traveler’s diarrhea. Gastroenterol Hepatol 2004; 19(6): 610–8CrossRefGoogle Scholar
  4. 4.
    DuPont HL. Travellers’ diarrhoea: contemporary approaches to therapy and prevention. Drugs 2006; 66(3): 303–14PubMedCrossRefGoogle Scholar
  5. 5.
    Okhuysen P, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774–8PubMedCrossRefGoogle Scholar
  6. 6.
    Caeiro JP, DuPont HL. Management of travellers’ diarrhoea. Drugs 1998; 56(1): 73–81PubMedCrossRefGoogle Scholar
  7. 7.
    DuPont HL, Mattila L. Antimicrobial treatment: an algorithmic approach. In: Ericsson CD, DuPont HL, Steffen RS, editors. Travelers’ diarrhea. Hamilton (ONT): BC Decker Inc, 2003: 227–37Google Scholar
  8. 8.
    Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller’s diarrhoea. Drugs 2005; 65(12): 1697–713PubMedCrossRefGoogle Scholar
  9. 9.
    Gascon J, Corachan M. Aetiology, epidemiology, and management of traveller’s diarrhoea. Rev Med Microbiol 2003; 14(3): 73–8CrossRefGoogle Scholar
  10. 10.
    Ericsson CD. Safety and tolerability of the antibacterial rifaximin in the treatment of travellers’ diarrhoea. Drug Saf 2006; 29(3): 201–7PubMedCrossRefGoogle Scholar
  11. 11.
    Salix Pharmaceuticals Inc. Xifaxin (rifaximin) prescribing information. Morrisville (NC), 2005 OctGoogle Scholar
  12. 12.
    DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 Dec 1; 33: 1807–15PubMedCrossRefGoogle Scholar
  13. 13.
    FDA. Medical review: application number 21–361. Clinical study RFID3001 [online]. Available from URL: [Accessed 2006 Apr 26]
  14. 14.
    Steffen R, Sack DA, Riopel L, et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 May; 98: 1073–8PubMedCrossRefGoogle Scholar
  15. 15.
    Infante RM, Ericsson CD, Jiang ZD, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004 Feb; 2(2): 135–8PubMedCrossRefGoogle Scholar
  16. 16.
    DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 Nov; 10(11): 1009–11PubMedCrossRefGoogle Scholar
  17. 17.
    DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998; 59(6): 708–14PubMedCrossRefGoogle Scholar
  18. 18.
    De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12(12): 979–81PubMedGoogle Scholar
  19. 19.
    DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005 May 17; 142(10): 805–12PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Personalised recommendations